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Abstract
Infection by the human immunodeficiency virus (HIV) is characterized by functional impairment and chronic activation of T
lymphocytes, the causes of which are largely unexplained. We cultured peripheral blood mononuclear cells (PBMC) from
HIV-uninfected donors in the presence or absence of HIV. HIV exposure increased expression of the activation markers CD69
and CD38 on CD4 and CD8 T cells. IFN-a/b, produced by HIV-activated plasmacytoid dendritic cells (pDC), was necessary
and sufficient for CD69 and CD38 upregulation, as the HIV-induced effect was inhibited by blockade of IFN-a/b receptor and
mimicked by recombinant IFN-a/b. T cells from HIV-exposed PBMC showed reduced proliferation after T cell receptor
stimulation, partially prevented by 1-methyl tryptophan, a competitive inhibitor of the immunesuppressive enzyme
indoleamine (2,3)-dioxygenase (IDO), expressed by HIV-activated pDC. HIV-induced IDO inhibited CD4 T cell proliferation by
cell cycle arrest in G1/S, and prevented CD8 T cell from entering the cell cycle by downmodulating the costimulatory
receptor CD28. Finally, the expression of CHOP, a marker of the stress response activated by IDO, was upregulated by HIV in
T cells in vitro and is increased in T cells from HIV-infected patients. Our data provide an in vitro model for HIV-induced T cell
dysregulation and support the hypothesis that activation of pDC concomitantly contribute to phenotypic T cell activation
and inhibition of T cell proliferative capacity during HIV infection.
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Introduction
Infection by the human immunodeficiency virus (HIV) type 1
causes a chronic, progressive and eventually deadly impairment of
immune function in humans [1]. Although HIV can infect most
CD4-expressing cells, particularly CD4 T helper cells, it is
accepted that infection of this cell subset cannot solely explain
the HIV-associated immunopathogenesis [2,3]. Multiple evidence
supports the hypothesis that the key events of HIV pathogenesis
reside in the complex interactions between the virus and the
immune system, for example: 1) the frequency of infected CD4 T
cells is too low to uniquely account for their depletion and
dysfunction [4,5]; 2) a large proportion of circulating virus is
estimated to be non productively infectious, but may still interact
with the immune system [6,7]; 3) cells that are not susceptible to
infection, such as CD8 T cells and B cells, also show signs of
functional impairment [8,9]; and 4) signs of chronic immune
activation, such as expression of T cell activation markers and
lymphoadenopathy, are observed during the infection and
correlate with disease progression [10–13].
The impairment of T cell responses in HIV infected patients has
been described both in vitro and in vivo [14,15]. HIV-infected
patients show reduced delayed hypersensitivity skin test reactions
and inefficient responses to common vaccines [15,16]. The in vitro
proliferative response to recall antigens is lost early during
infection, and is followed by loss of response to alloantigens and
mitogens [14]. The loss of T cell function progresses during the
course of HIV disease, and is predictive of AIDS onset and death
[14,15]. Immune exhaustion, caused by chronic T cell activation,
is one of the most supported theories which could explain the
HIV-associated immunodeficiency [13,17]. Compelling evidence
for the role of chronic T cell activation in HIV pathogenesis comes
from the observation that not only the expression of certain surface
activation markers, such as CD69 or CD38, is increased on T cells
from HIV-infected patients [18,19], but also that the frequency of
CD38+ CD8 T cells is the best predictor of disease progression,
better than plasma viral load and CD4 count [10,12]. Further-
more, signs of T cell activation are not observed in natural hosts of
HIV and simian immunodeficiency virus (SIV), species that do not
develop immunologic disease despite high levels of viral replication
[13,20].
Several mechanisms are thought to contribute to T lymphocyte
activation and exhaustion. Of these, the two most frequently cited
are 1) the constant antigenic stimulation caused by HIV
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replication, combined with the lymphotropic nature of the virus,
which may chronically trigger T lymphocytes [13,17]; and 2) the
presence of circulating immunostimulatory factors of microbial
origin, such as lipopolisaccaride, which translocate from the
damaged gut mucosa during the early phases of acute infection
and may provide a constant stimulus for T cells and innate
immunity [17,21,22]. The extent of the contribution of both these
mechanisms, and of others, is unclear and is subject of discussion.
The reactivation of latent viral infections, such as CMV or EBV,
due to the reduction of immune control, as well as the occurrence
of other opportunistic infections, may also provide further
antigenic stimulation to T cells [23–26]. On the other hand,
chronic activation of innate immunity may derive not only from
microbial bioproducts [17,22], but also from direct activation of
plasmacytoid dendritic cells (pDC) by HIV [27].
pDC are important players in innate immune responses against
viral infections [28,29]. They can be activated by HIV in a CD4-
dependent manner to produce large amounts of type I interferon
(IFN) [30,31], and to express the tryptophan-catabolizing enzyme
indoleamine-2,3-doxygenase (IDO) [32]. As an alternative to the
T cell activation hypothesis, we recently proposed that the chronic
activation of pDC by direct interaction with infectious and
noninfectious HIV particles may be the main driving force for
HIV disease progression [27]. Thus, the proapoptotic effect of
type I interferon, combined with the immunesuppressive function
of IDO and its interaction with regulatory T cells, may contribute
to both the progressive depletion of CD4 T cells and their
functional impairment [27,33–35]. It is noteworthy that high IFN-
a production and IDO activity are detected both in the circulation
and in lymphoid tissues during HIV/SIV infection [31,32,36–39].
Here we show that in vitro HIV-induced IFN-a production
stimulates an activated phenotype in both CD4 and CD8 T cells,
characterized by increased expression of CD69 and CD38.
However, T lymphocytes from HIV-exposed peripheral blood
mononuclear cells (PBMC) are unresponsive to subsequent T cell
receptor (TCR) stimulation, and this unresponsiveness is partially
mediated by HIV-induced IDO activity. We then describe, using a
two-step experimental protocol, that HIV-stimulated IDO affects
T cell activity by arresting CD4 T cells in the G1 phase of the cell
cycle, and by inducing CD28 downregulation by CD8 T cells.
Finally, we show that the expression of CHOP, a marker of the
stress-response system activated by IDO-induced tryptophan
deprivation [40], is increased in vitro by HIV and is elevated in
lymphocytes from HIV-infected patients.
Results
HIV-induced type I IFN upregulates the T cell activation
markers CD69 and CD38
Elevated expression of certain surface markers is regarded as a
hallmark of chronic T cell activation during HIV infection and is
predictive of disease progression [10,12,18,19]. We tested whether
direct exposure of PBMC from HIV-uninfected donors to
infectious or RT-deficient (AT-2) HIV would affect expression of
the activation markers CD69 and CD38 on CD4 and CD8 T cells.
Flow cytometry analysis revealed a significant increase in CD69
and CD38 on CD4 (Fig. 1A and 1B) and CD8 T cells (Fig. 1C and
1D) after 24 and 48 hours of incubation with HIV, measured both
as proportion of marker-expressing cells (Fig. 1A and 1C) and
mean fluorescence intensity (MFI) (Fig. 1B and D). Because
antigen recognition and T cell receptor (TCR) engagement are
unlikely to occur in this in vitro setting within 24 hours, we
reasoned that the mechanism of CD69 and CD38 induction would
be independent of classic T cell activation.
Type I IFN is rapidly produced by pDC upon exposure to HIV
and can directly affect T cell phenotype and function [30,31,41].
In the present study IFN-a levels in supernatants of HIV-exposed
PBMC were 438.56208.9 pg/ml and 511.2+237.1 pg/ml after
24 hours and 48 hours, respectively. IFN-a was below 40 pg/ml
in supernatants of untreated PBMC at both time points. We tested
whether type I IFN may contribute to the HIV-induced expression
of CD69 and CD38. Blocking antibodies directed against the
subunit 2 of the IFN receptor (anti-IFNAR), specific for IFN-a,
largely prevented the induction of CD69 and CD38 on CD4
(CD69 and CD38 MFI reduction of 7568% and 62619%,
respectively) (Fig. 1A and 1B) and CD8 T cells (CD69 and CD38
MFI reduction of 4468% and 4562%, respectively) (Fig. 1C and
1D) after 24 and 48 hours. No effect was observed when
antibodies against the receptor subunit specific for IFN-c (anti-
IFNGR) were used (data not shown). Furthermore, culture of
PBMC from HIV-uninfected donors in the presence of recombi-
nant human IFN-a resulted in increased CD69 and CD38
expression on CD4 (Fig. 2, left panels) and CD8 T cells (Fig. 2,
right panels), similar to that observed after exposure to HIV.
These data collectively suggest that HIV-induced type I IFN
may contribute to the maintenance of a chronic activated T cell
phenotype, even in the absence of classic antigenic triggers for T
cell activation.
In vitro exposure to HIV impairs proliferative T cell
responsiveness, role of HIV-induced IDO
We tested whether the induction of an activated phenotype on
CD4 and CD8 T cells after exposure to HIV corresponded to
increased proliferative responses. CFSE-labeled PBMC from three
HIV-uninfected donors were cultured in the presence or absence
of HIV for 24 hours. These cells were then stimulated with anti-
CD3 (OKT3) antibodies. Proliferation of CD4 and CD8 T cells
was evaluated after 3 days by CFSE dilution. Pre-treatment with
HIV significantly inhibited proliferation of both CD4 and CD8 T
cells, expressed by both division and proliferation indices (Fig. 3A
upper panels and Fig. 3B). Because we previously reported that
HIV induces pDC to express the immunosuppressive enzyme
IDO [32], we tested whether blockade of IDO with the
competitive inhibitor 1mT would counteract the anti-proliferative
effect of HIV exposure. Preincubation of PBMC with 1mT
partially prevented the proliferative defect induced by HIV in
CD4 and CD8 T cells (Fig. 3A lower panels and Fig. 3B).
Statistically significant 1mT-induced increases were observed for
both CD4 and CD8 T cells in the division indices, while increases
in the proliferation indices only approached statistical significance
(Fig. 3B). Multiple downregulatory mechanisms may be activated
by HIV and act alongside IDO in suppressing T cell responses.
For example, HIV-mediated induction of CD4 T cell apoptosis
[41], of the negative regulator PDL-1 [42–44] and of regulatory T
cell survival [39] may all affect T cell responses in an IDO-
independent way.
To better investigate the contribution of IDO to HIV-induced
impairment of T cell responses, we designed a 2-step experimental
model. Using this experimental design, T cells were exposed to an
HIV-induced tryptophan-depleted environment, while their direct
contact with pDC and monocytes which express proapoptotic and
antiproliferative molecules such as PDL-1 and tumor necrosis
factor family members was limited. We cultured PBMC from
HIV-uninfected donors in the presence or absence of HIV, with or
without 1-mT, for 48 hours. Supernatants were then collected and
used as conditioned media (CM: control, HIV, HIV+1mT), as
described in Material and Methods. We used these CM to culture
autologous CD4 and CD8 T cells, in the presence or absence of
HIV-Induced T Cell Dysfunction
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anti-CD3 (OKT-3) and anti-CD28 antibodies (complete absence
of pDC from CD4 T cells is shown in Supplemental Figure S1).
After three days, proliferation was evaluated as increase in the
number of viable cells, measured using a bioreduction colorimetric
assay. Anti-CD3/28-induced proliferation was reduced in CD4
and CD8 T cells cultured in HIV CM compared to both control
CM and HIV+1mT CM (Fig. 4A). Control experiments were
performed by culturing CD4 T or CD8 T cells in fresh media, in
the presence or absence of HIV or HIV plus 1mT, to distinguish
between the effect of tryptophan depletion and the direct
cytopathic effect of HIV which may still be present in the CM.
Direct exposure to HIV showed no significant effect on the
proliferative response of CD4 T and CD8 T cells, nor did addition
of 1-mT (data not shown). Our in vitro model demonstrates that
HIV-induced tryptophan catabolism has a direct negative effect on
CD4 and CD8 T cell proliferative responses.
Figure 1. HIV induces increased CD69 and CD38 on T cells in a type I IFN-dependent manner. PBMC from HIV-uninfected donors were
cultured for 24 and 48 hours in presence of control microvescicles, HIV alone or in presence of blocking antibodies against the cellular receptor for
IFN-a (anti-IFNAR). CD38 and CD69 expression were analyzed by flow cytometry on gated CD3+CD4+ and CD3+CD8+ cells (CD4 and CD8 T cells,
respectively). (A) and (C) show flow cytometry contour plots of CD69 and CD38 expression for one example experiment for CD4 and CD8 T cells,
respectively. (B) and (D) show bar graphs summarizing mean fluorescence intensity (MFI) of CD38 and CD69 in CD4 and CD8 T cells, respectively
(48 hours only). Mean values6standard error calculated on 5 independent experiments are shown in the bar graphs.
doi:10.1371/journal.pone.0002961.g001
HIV-Induced T Cell Dysfunction
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The antiproliferative effect of IDO is not associated with
increased apoptosis
We analyzed the induction of apoptosis in CD4 and CD8 T
cells cultured in the CM. The percentage of cells expressing the
apoptotic marker annexin V was measured by flow cytometry.
Culture in HIV CM or HIV+1mT CM did not result in increased
apoptosis of CD4 or CD8 T cells compared to control CM
(Fig. 4B), suggesting that HIV-induced, IDO-mediated inhibition
of T cell proliferation is not due to increased apoptosis.
HIV-induced tryptophan catabolism inhibits CD4 and CD8
T cell proliferation at different stages of the cell cycle
We tested whether cell cycle progression was affected in CD4
and CD8 T cells stimulated in the CM. BrdU incorporation and
DNA content (7-AAD staining) were analyzed by flow cytometry.
The percentage of both CD4 and CD8 T cells in the G0/G1
phases of the cell cycle was increased, whereas that of cells in the S
phase was decreased when cells were stimulated in HIV CM
compared to both control CM and HIV+1mT CM (Fig. 5A).
Because the BrdU/7-AAD staining does not permit precise
discrimination between cells stationing in G0 and cells that have
entered the cell cycle but are stopped in the G1 phase, we analyzed
mRNA expression for cyclin D1 (typically expressed in G1 phase)
and cyclin E1 (typically expressed in late G1 and S phase). We
found that CD4 T cells upregulated cyclin D1 expression in HIV
CM at levels comparable to control CM and HIV+1mT CM.
However, CD4 T cells cultured in HIV CM failed to upregulate
cyclin E1 (Fig. 5B, upper panels). Conversely, upregulation of both
cyclin D1 and cyclin E1 was impeded in CD8 T cells by culture in
HIV CM, compared to both control CM and HIV+1mT CM
(Fig. 5B, lower panels).
Downregulation of CD28 expression has been reported for CD8
T cells from HIV-infected patients [45,46], and has been
described as a potential consequence of tryptophan starvation in
a murine model [47]. Therefore, we tested whether CD28 mRNA
expression in CD8 T cells was affected by culture in the CM. We
found a progressive decrease of CD28 mRNA expression by CD8
T cells cultured for 3 days in any of the three CM (Fig. 5C). Such
decrease was significantly enhanced in HIV CM, compared to
both control CM and HIV+1mT CM (Fig. 5C). No alteration of
CD28 expression was observed in CD4 T cells cultured in HIV
CM compared to control CM (data not shown)
These data collectively suggest that HIV-induced tryptophan
catabolism has different effects on CD4 and CD8 T cells, resulting
in the arrest of CD4 T cells at the G1/S transition checkpoint of
the cell cycle and in the downregulation of CD28 expression by
CD8 T cells, which eventually prevents their entry into the cell
cycle due to insufficient costimulation.
HIV activates the GCN2-stress-response system in vitro
and in vivo
The immediate effect of tryptophan depletion at the molecular
level is the increase in cytoplasmic uncharged tRNAtrp [40].
Similar to other cell types, T lymphocytes are sensitive to changes
in uncharged tRNA levels, which serve as a monitor for
availability of free amino acids [40]. Accumulation of uncharged
tRNAtrp results in activation of the stress-response system
regulated by the GCN2 kinase [40]. The CHOP gene (also
known as gadd153) is a well-accepted marker for GCN2 activation
[40]. We analyzed CHOP mRNA expression in CD4 and CD8 T
cells cultured in the CM. CHOP expression was increased in both
CD4 (2-fold) and CD8 T cells (1.5-fold) cultured in HIV CM
compared to both control CM and HIV+1mT CM (Fig. 6A). We
then tested CHOP mRNA expression in CD4+ and CD8+ cells
isolated from fresh PBMC of HIV-infected individuals (HIV+) and
uninfected blood bank donors (HC). Both CD4+ and CD8+ cells
from HIV+ patients with detectable plasma virus level (.50
copies/ml) expressed significantly higher levels of CHOP com-
pared to HIV+ patients with undetectable plasma virus level (,50
copies/ml) and HC (Fig. 6B). Only a trend to increased CHOP
mRNA, approaching statistical significance, was observed in
HIV+ patients with undetectable plasma virus level (,50
copies/ml) compared to HC (Fig. 6B). Increased CHOP
expression did not appear to be directly connected with lack of
HAART regimen, but rather with viral replication, measured as
Figure 2. rIFN-a induces increased CD69 and CD38 on T cells. PBMC from HIV-uninfected donors were cultured for 24 (upper panels) and
48 hours (lower panels) in presence or absence of recombinant IFN-a (rIFN-a). CD38 and CD69 expression were analyzed by flow cytometry on gated
CD3+CD4+ and CD3+CD8+ cells (CD4 and CD8 T cells, respectively). Flow cytometry contour plots of CD69 and CD38 expression for one example
experiment for CD4 (left panels) and CD8 T cells (right panels).
doi:10.1371/journal.pone.0002961.g002
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plasma virus load (compare triangles and circles in Fig 6B). These
results demonstrate that HIV activates the GCN2 stress response
system in CD4 and CD8 T cells in an IDO-dependent manner, and
that signs of GCN2 activation are observed in lymphocytes from
HIV-infected patients in whom viral replication is highly active.
Discussion
The underlying causes of HIV-driven immunedeficiency are still
poorly understood. The high level of expression of T cell activation
markers detected in HIV-infected patients during disease progres-
sion, together with the fact that expression of such markers is not
altered in natural resistant hosts of HIV/SIV, has attracted attention
by the scientific community [3,10,12,13,20,48,49]. Although viral
replication is considered to be responsible for the chronic T cell
activation, the cellular and molecular bases of HIV-induced T cell
exhaustion are not fully understood. Based on the growing body of
evidence showing potential pathogenic effects of HIV-induced
activation of pDC, we recently proposed that chronic activation of
innate immune responses, rather than direct T cell activation, may
play a major role in HIV pathogenesis [27]. Here we provide a link
between HIV-induced activation of innate and adaptive immunity,
by showing that signs of T cell activation can be induced by HIV-
triggered production of IFN-a. Furthermore, we show that
Figure 3. HIV exposure impairs T cell proliferative responses, contribution of IDO-mediated tryptophan catabolism. CFSE-labeled
PBMC from HIV-uninfected donor were cultured for 24 hours in presence of control microvescicles, HIV alone, or in presence of the IDO inhibitor 1-
methyl-D-tryptophan (1mT). After 24 hours anti-CD3 was added to the cultures and cells were analyzed by flow cytometry after 72 hours. (A) Flow
cytometry histograms showing CFSE dilution for one example experiment for CD4 (left panels) and CD8 T cells (right panels) are shown. Upper panels
show the comparison between control-pretreated cells (green line) and HIV-pretreared cells (red line); bottom panels show the comparison between
HIV-pretreared cells (red line) and cells pretreated with HIV in presence of 1mT (Blue line). One representative of 5 independent experiments is
shown. (B) Bar graphs showing division index (number of cell divisions/total cell number) and proliferation index (number of cell divisions/number of
divided cells) of CD4 (left panels) and CD8 T cells (right panels) pretreated with AT-2 HIV or mock and stimulated with anti-CD3 in presence (solid
bars) or absence (open bars) of 1mT. Mean values6standard error calculated on 5 independent experiments are shown.
doi:10.1371/journal.pone.0002961.g003
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impairment of T cell proliferative responses induced by HIV can be
replicated in vitro by exposure of uninfected leukocytes to the virus,
and that at least part of this dysfunction is dependent on IDO-
mediated tryptophan catabolism.
Our findings presented here raise the possibility that phenotypic
signs of CD4 and CD8 T cell activation can be induced by HIV in
the absence of antigen presentation or TCR engagement. Both the
activation marker CD69 and CD38, commonly used to define the
chronically activated status of T cells from HIV-infected patients
[10,12,18,19], were increased in a type I IFN-dependent manner
by exposure to HIV. Although we cannot exclude that other
immunologic pathways triggered by HIV may contribute to the
induction of a T cell activated phenotype in vivo, our results that
rIFN-a is sufficient to upregulate CD69 and CD38, combined
with the reports of elevated levels of type I IFN in plasma and
tonsils of HIV-infected patients [22,38,41], suggest that IFN-a
contributes to inducing and maintaining the activated T cell
phenotype characteristic of HIV disease progression. In vitro
induction of CD38 and CD69 was described in response to
different TLR ligands, including TLR9 agonists [50], suggesting
that stimulation of innate immune responses through different
routes may contribute to the activated T cell phenotype observed
in HIV-infected patients. The hypothesis recently proposed by
Brenchley and colleagues on microbial translocation fits well in
this view, in that lipopolisaccaride (LPS) and other microbial
components, systemically mobilized from the gut, may function as
chronic stimuli resulting in phenotypic T cell activation [22].
However, our findings presented here suggest that even in the
absence of other microbial components, either derived from
opportunistic infections or translocated from the damaged gut,
HIV-mediated activation of innate immune responses, particularly
those associated with type I IFN production, may be sufficient to
trigger the appearance of an activated T cell phenotype. Although
a direct correlation between plasma type I IFN and expression of
phenotypic activation markers has not been reported in HIV-
infected patients, both these parameters have been described to
correlate with plasma virus levels or CD4 count [18,19,34,51,52],
suggesting a tight connection among T cell activation, type I IFN
production and disease progression.
Similar to what observed in lymphocytes from HIV-infected
patients, CD4 and CD8 T cells from in vitro HIV-exposed PBMC
showed impaired proliferative capacity when stimulated through
classic TCR signalling (anti-CD3 and anti-CD28). Thus, despite
carrying phenotypic signs of activation, T cells from HIV-exposed
leukocytes have impaired proliferative capacity, which is a key
feature of HIV disease [14–16]. A similar combination of
immunedeficiency despite phenotypic signs of T cell activation
was described in mice treated with repeated administration of
CpG oligonucleotides, which are powerful activators of pDC [53].
Of note, CpG-treated mice also showed severe lymphoadenopathy
and T cell depletion, two other alterations normally observed
during HIV disease [53]. All of these symptoms appeared to be
milder or absent in IFNAR knock-out mice, demonstrating that,
whereas brief activation of pDC may potently enhance the
induction of efficient T cell responses [54], prolonged hyperactiva-
tion of type I IFN signalling may have deleterious effect on the
adaptive immune system [27,53].
It is still controversial whether type I IFN production is
increased or reduced during HIV infection. Reports documenting
decreased type I IFN responses after in vitro stimulation of
leukocytes from HIV-infected patients compared to uninfected
controls suggest that pDC function is impaired [55–58]. However,
these reports are partially influenced by the reduced frequency of
pDC in the circulation during HIV infection which could be a
consequence of the relocation of these cells to lymphoid organs
[38,59–61]. Although two distinct studies failed to identify pDC in
lymphoid tissues of HIV infected patients with low CD4 counts
and in macaques infected by SIV in end stage, none of them
analyzed the actual levels of type I IFN in the tissues, making it
hard to interpret their conclusions [62,63]. In addition, a strong
increase of pDC density in the T cell zone in lymph nodes of
Figure 4. HIV-induced IDO suppresses both CD4 and CD8 T cell
proliferation in a 2-step experiment. (A) CD4 and CD8 T cell
proliferation is shown as the increase in the number of viable cells
measured using a bioreduction assay. Relative cell number was
calculated for each sample as ratio between stimulated (with anti-
CD3 and anti-CD28) and unstimulated cells cultured in the three
different conditioned media (CM). (B) CD4 and CD8 T cell apoptosis is
shown as frequency of annexin V+ cells measured by flow cytometry.
Apoptosis of cells cultured in the three different conditioned media
(CM) is shown for both unstimulated and stimulated (with anti-CD3 and
anti-CD28) cells. In all cases mean values6standard error calculated on
8 independent experiments are shown.
doi:10.1371/journal.pone.0002961.g004
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Figure 5. Effect of HIV-induced IDO on CD4 and CD8 T cell cycle progression in a 2-step experiment. (A) Flow cytometry dot plots
showing BrdU incorporation and DNA staining with 7-AAD for one example experiment for CD4 and CD8 T cells stimulated with anti-CD3 and anti-
CD28 in the three different conditioned media (CM); red boxes indicate gates for cells in G0/G1, S and G2 phase; numbers represent the percentage
of T cells in S phase for each condition. (B) Cyclin D1 (marker of G1 phase) and cyclin E1 (marker of S phase) mRNA expression in CD4 and CD8 T cells
stimulated in the three different conditioned media (CM). Relative mRNA levels are calculated as ratio between stimulated (with anti-CD3 and anti-
CD28) and unstimulated cells. (C) CD28 mRNA expression in unstimulated CD8 T cells cultured in the three different conditioned media (CM) over a
72 hours period. In all bar graphs mean values6standard error calculated on 8 independent experiments are shown.
doi:10.1371/journal.pone.0002961.g005
HIV-Induced T Cell Dysfunction
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asymptomatic HIV infected patients was reported in an earlier
study [64], supporting the hypothesis that pDC may relocate to
lymphoid tissues at least in asymptomatic stage. Furthermore, it
has been recently shown that pDC are indeed chronically
stimulated in HIV-infected patients and produce type I IFN,
which in turn contributes to their hyporesponsiveness to
subsequent in vitro stimulation, probably through a negative
regulatory feedback mechanism [65]. The elevated expression of
type I IFN-inducible genes at both peripheral and tissue level in
HIV-infected patients is also evidence of chronic production of
these cytokines [38,66]. The question can be raised as to why HIV
is, compared to other viruses, particularly efficient in inducing
chronic pDC activation. We proposed that the expression of CD4,
the main receptor for HIV, on the surface of pDC, may render
them particularly susceptible to HIV-induced activation [27].
Thus, gp120-CD4 interaction is required for endocytosis of HIV
by pDC and subsequent triggering of TLR7 [30,31,67] and the
association of CD4 to a clathrin-dependent endocytotic machinery
Figure 6. CHOPmRNA expression is upregulated in CD4 and CD8 T cells by HIV-induced IDO in vitro and in HIV-infected patients in
vivo. (A) CHOP mRNA expression in unstimulated CD4 and CD8 T cells cultured in the three different conditioned media (CM). Mean
values6standard error calculated on 8 independent experiments are shown. (B) Plots showing CHOP mRNA expression in CD4+ and CD8+ cells
isolated from PBMC of uninfected healthy controls (HC) and HIV-infected patients (HIV+) with plasma virus levels below (VL,50) or above (VL.50)
the detection threshold. Each symbol represents one individual patient or donor: HC are indicated with squares; HIV-infected patients undergoing
HAART are indicated with circles (independently of plasma virus load) and HIV-infected patients not undergoing HAART are indicated with triangles
(independently of plasma virus load). Horizontal bars represent mean values for HC, HIV+ VL,50 and HIV+ VL.50, respectively.
doi:10.1371/journal.pone.0002961.g006
HIV-Induced T Cell Dysfunction
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[68,69] may greatly facilitate the endocytosis of HIV and
subsequent pDC activation [27]. Moreover, monocytes and
macrophages have been shown to produce type I IFN and express
IDO when exposed to or infected by HIV, or when exposed to
HIV-derived proteins [70–74]. Thus, alternative sources of both
type I IFN and IDO may contribute to the described mechanisms
during HIV infection.
We previously demonstrated that HIV-induced type I IFN
contributes to CD4 T cell apoptosis by inducing expression of pro-
apoptotic molecules of the tumor necrosis factor (TNF) superfam-
ily [31,41]. The HIV CM used in this study contain type I IFN in
concentrations comparable to those required for the induction of
CD4 T cell apoptosis [31,41], and HIV viral particles may still be
present in the same HIV CM. However, in the present study, we
did not observe any increase in CD4 T cell apoptosis in the two-
step experiment when HIV CM was used. This apparent
contradiction is explained by the fact that type I IFN is sufficient
and necessary to induce expression of apoptotic ligands, such as
TNF-related apoptosis-inducing ligand (TRAIL), but not of their
cellular death receptors (DR), such as DR5, which are required for
CD4 T cell apoptosis [31,34,41]. Of note, in the present study,
direct exposure of unseparated PBMC to HIV for 24 or 48 hours
resulted in CD4 T cell apoptosis, similar to what described in our
previous reports [31,34,41]. Engagement of CD4 expressed on T
cells by gp120 and/or the contribution of other cellular subsets
may be required to result in DR5 expression by CD4 T cells and
subsequent apoptosis [34]. One example of these accessory cells is
that of pDC themselves, which are completely absent from the
CD4 T cell culture in this study (see Supplemental Figure S1) and
can express TRAIL and induce CD4 T cell apoptosis when
exposed to HIV or type I IFN [67]. The two-step experiment
described in this study was designed for the purpose of focusing
our analysis on HIV-induced, IDO-mediated tryptophan catab-
olism, thus limiting the interference by other mechanisms triggered
by HIV, including those involving CD4 T cell apoptosis.
The pleiotropic effects of type I IFN and other immunologic
mechanisms induced by HIV exposure may all contribute to the
suppression of proliferative responses. Here we focused on the
catabolism of tryptophan through the enzymatic reaction catalized
by IDO, which we previously described to be induced by HIV in
pDC through a mechanism that is independent of production of
either type I or type II IFN [32], which are the major known
inducers of IDO in both human and murine cells [75]. We found
that HIV-induced IDO is partially responsible for the proliferative
impairment of T cells, and that it differentially affects CD4 and CD8
T cells. The fact that inhibition of IDO had only a limited beneficial
effect on CD4 and CD8 T cell proliferation is in accordance with our
previously published data, showing a significant albeit limited
recovery of proliferative responses by CD4T cell fromHIV+ patients
[32]. It should be noted that the extent of the proliferative defect and
of its correction by IDO blockademay depend in vivo on the levels of
viral replication and on the number of circulating CD4 T cells.
Indeed, we previously reported that the increase in proliferation
induced by 1-mT in PBMC from HIV+ patients directly correlates
with the CD4 count [32]. Importantly, several reports have
described elevated IDO expression in lymphoid tissues, including
tonsils, lymph nodes, spleen and the gut-associated lymphoid tissue,
during different stages of HIV and SIV infection [36,37,39,76,77],
suggesting that the effects of tryptophan depletion on T cells may be
enhanced in lymphoid tissues.
A recent study has identified an isoform of IDO, named IDO2,
which appears to be the preferential target of the D-isomer of 1mT
we used in the present study [78]. Notably, IDO2 has reduced
enzymatic activity compared to IDO, but exerts potent immune-
suppressive effect, similar to IDO, which can be inhibited by D-
isomeric 1mT [78]. It is therefore likely that part of the recovery of
T cell proliferation observed in the present study in presence of
1mT is the consequence of blockade of IDO2, rather than IDO.
However, we have previously used D-isomeric 1mT to successfully
inhibit in vitro HIV-induced tryptophan degradation and
kynurenine production [32], suggesting that this molecule has a
significant effect on tryptophan catabolism, whether mediated by
IDO or IDO2. Furthermore, in the same study, D-isomeric 1mT
was efficient in improving in vitro proliferative responses of T cells
from HIV-infected patients [32], confirming its biologic activity. It
is unclear whether the immunoregulatory activity of IDO (or
IDO2) is the consequence of tryptophan depletion, accumulation
of kynurenine bioproducts or a combination of both mechanisms.
The limitation of tryptophan availability appears to be sufficient to
induce activation of the GCN2 stress response system, which is
normally triggered by amino acid depletion[40]. However,
Fallarino and colleagues reported that both reduction of
tryptophan and addition of downstream bioproducts of the
kynurenine pathway are required to alter CD4 and CD8 T cell
phenotype and function in a GCN2-dependent manner [47]. The
use of 1mT to interfere with HIV-induced IDO activity has the
great advantage of limiting both mechanisms, inhibiting trypto-
phan conversion into kynurenine [32]. On the contrary,
supplementation of exogenous tryptophan does not have any
effect on kynurenine production. Furthermore, two clinical trials
are currently enrolling volunteers for studying the safety of
administration of the D-isomeric 1mT for the treatment of
metastatic or refractory solid tumors (clinicaltrials.gov; identifier
NCT00567931 and NCT00617422), rendering this molecule a
good candidate for testing its potential efficacy for improving the
immune function in HIV-infected patients in the future.
We and others have previously reported that CD4 and CD8 T
cells are differently affected by tryptophan catabolism [32,47,79].
In the present study we observed that both cell types are negatively
affected by HIV-induced IDO. CD4 T cells are activated by TCR
signalling to enter the G1 phase of the cell cycle but cannot
progress further through the S phase. In contrast, CD8 T cells
downregulate CD28 expression which deprives them of the
costimulatory signal during TCR engagement, therefore prevent-
ing their entry into the cell cycle. CD28 downregulation is
characteristic of CD8 T cells from HIV-infected patients, and
contributes to their limited responsiveness to viral antigens,
including against HIV [45,46]. Our data presented here, together
with similar findings obtained in a murine model [47] suggest that
HIV-induced tryptophan catabolism may be at least partially
responsible for CD28 downregulation on CD8 T cells from HIV-
infected patients. The in vitro effect of HIV-induced IDO on both
CD4 and CD8 T cells was associated with increased expression of
CHOP, symptomatic of activation of the GCN2-mediated stress
response. Remarkably, such increase was still detectable in
circulating CD4+ and CD8+ cells from HIV-infected patients in
whom viral replication was active.
Our previous report indicated that the in vitro proliferative
defect of CD4, but not CD8 T cells from HIV-infected donors
could be corrected by addition of 1mT [32], which is in apparent
contrast with the IDO effect on both CD4 and CD8 T cells that
we described here. However, in the in vitro system employed in
the present study, 1mT is used to prevent HIV-induced
tryptophan depletion rather than correct the existing impairment.
It is therefore possible that simple addition of 1mT to PBMC
cultured ex vivo from HIV-infected patients [32] may not restore
CD28 expression and proliferative response on CD8 T cells, but
may be sufficient to release the block on CD4 T cell cycle
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progression. In addition, other immunologic mechanisms have
been described that suppress both CD4 and CD8 T cell responses
in HIV-infected patients, whereas the present study was designed
with the precise purpose of isolating the effects of tryptophan
catabolism from other HIV-induced dysfunctions.
The effect of IDO-mediated tryptophan catabolism onCD4 T cell
cycle progression provides a potential advantage for HIV infection
and persistence. HIV efficiently infects cycling CD4 T cells, but is
incapable of completing reverse transcription in quiescent cells
stationed in the G0 phase of the cell cycle [80]. Interestingly, arrest of
the cell cycle in the late G1 phase does not interfere with reverse
transcription [80], but progression through the cell cycle is required
for the production of new viruses [81]. Thus, CD4 T cells which are
arrested in the G1 phase by HIV-induced IDO may represent a
target for HIV infection, but not a source of new viruses. Such cells
could be frozen in a stage in which HIV proviral DNA is safely
integrated in the genome, but the lack of production of viral proteins
may prevent their recognition by HIV-specific cytotoxic T
lymphocytes. We raise the possibility that CD4 T cells arrested in
the G1 phase of the cell cycle may contribute to the ‘‘hidden
reservoir’’ of HIV-infected cells which persists through the course of
infection. Other cell cycle alterations have been described for T cells
from HIV infected patients, which may be caused by mechanisms
other than IDO and contribute to the same effect of maintaining a
pool of infected, inactive cells [82–84].
Our results provide the first evidence that phenotypic activation
markers can be induced by HIV on human T cells without the need
for productive infection or antigenic stimulation, but simply by
inducing type I IFN production. Such phenotypically activated T
cells have reduced expansion ability, and part of this impairment is
due to IDO. pDC have been largely described to be the cellular
source of both IDO and IFN-a/b [30,32,41,85], suggesting that
chronic stimulation of these mediators of innate immune responses
may contribute to both proliferative impairment and phenotypic
activation of T cells during HIV infection. The experimental design
on which this study is based may represent a simple in vitromodel for
HIV immunopathogenesis, which may be suitable for testing
candidate blockers of the interaction between HIV and immune
cells for their immunotherapeutic potential.
Materials and Methods
Isolation and culture of blood leukocytes
Blood samples were obtained from healthy donors under an
NIH IRB-approved protocol developed by the Department of
Transfusion Medicine, NIH, Bethesda, MD; and HIV-infected
patients (N= 25) who were involved in the USAF Natural History
Study. All blood samples were collected under protocols that were
reviewed and approved by the Institutional Review Boards of the
USAF Wilford Hall Medical Center, Lackland AFB, TX and of
the National Cancer Institute, Bethesda, MD. Eighteen of the
HIV-infected patients were receiving highly-active antiretroviral
therapy (HAART), consisting of a combination of two reverse-
transcriptase inhibitors and one protease inhibitor, at the time of
enrollment. Seven of the HIV-infected patients were HAART-free
at the time of enrollment. Plasma viral loads and CD4 counts for
all HIV-infected patients included in the study are summarized in
Table 1. HAART-treated patients had significantly lower viral
load compared to HAART-free patients (P = 0.004), whereas CD4
counts were not significantly different between the two groups
(P = 0.808). In vitro experiments were performed using peripheral
blood mononuclear cells (PBMC) isolated by density centrifugation
using peripheral blood lymphocyte separation medium (Cambrex,
Gaithersburg, MD). Cells were cultured in RPMI 1640 (Invitro-
gen, Gaithersburg, MD) containing 10% fetal bovine serum
(Hyclone, Logan, UT) and 1% Pen-Strep-Glut (Invitrogen).
Preparation of noninfectious AT-2 HIV-1
All virus preparations were kindly provided by Dr. Jeffrey D.
Lifson, National Cancer Institute, Frederick, MD. HIV-1MN (X4-
tropic) and HIV-1Ada (R5-tropic) were inactivated with 1 mM
Aldrithiol-2 (AT-2) for 18h at 4uC (AT-2 HIV-1), as described
[86]. Microvesicles, isolated from uninfected cell cultures were
employed as a negative control [86].
Stimulation and culture of PBMC
PBMC were cultured with noninfectious AT-2 HIVMN, AT-2
HIVAda or their non-AT-2-treated infectious counterparts at
300 ng/mL p24CA equivalent as previously described [31].
Experiments conducted using AT-2 HIVMN, AT-2 HIVAda or
non AT-2-treated infectious HIV-1MN or HIV-1Ada gave compa-
rable results. Only results obtained using AT-2 HIVMN are shown.
A mixture of 12 different species of rIFN-a (IFN-a sampler kit,
R&D Systems) was used at the final concentration of 1000 U/ml.
Blocking assays
Blocking of type I IFN receptor was performed by pre-
incubating PBMC with 5 mg/ml anti-IFNAR (Invitrogen) for
30 min before addition of AT-2 HIV. Isotype-matched antibodies
were used as controls.
Table 1. Patients clinical status
Patient # CD4 count Cells/ml VL copies/ml


























HIV-Induced T Cell Dysfunction
PLoS ONE | www.plosone.org 10 August 2008 | Volume 3 | Issue 8 | e2961
Flow cytometry
After stimulation in culture, cells were washed and incubated for
20 min at room temperature in PBS containing 2% mouse serum
(Sigma) with the following antibodies: Peridinn chlorophyll protein
(PerCP)-conjugated anti-CD3 (BD Biosciences), Allophycocyanin
(APC)-conjugated anti-CD4 (BD Biosciences), PE-Cy7-conjugated
anti-CD8 (BD Biosciences), Phycoerythrin (PE)-conjugated anti-
CD69 (BD Biosciences), fluorescein isothiocyanate (FITC)-conju-
gated anti-CD38 (BD Biosciences). Cells were washed twice in ice-
cold DPBS and FACS analysis was performed on a FACSCanto
flow cytometer using FACSDiva software (BD Biosciences).
FlowJo software (Treestar, Ashland, OR) was used to analyze
flow cytometry data.
Inhibition of IDO with 1-methyl tryptophan
The D-isomer of 1-methyl tryptophan (1mT) was used in all
IDO-blocking experiments. The D-isomer was chosen because we
have previously shown its efficacy in inhibiting HIV-induced
degradation of tryptophan and production of kynurenine [32].
1mT (Sigma) was suspended in deionized water and solubilized by
addition of NaOH. HCl was subsequently added to adjust the pH
to 7.4. A solution of NaOH and HCl in water prepared in the
same conditions as the 1mT was used as negative control.
CFSE proliferation experiment
CFSE-labeled PBMC from five different donors were cultured
in presence or absence of AT-2 HIV as described above, with or
without 1-methyl-D-tryptophan (1mT, 200 mM) (Sigma). After
24 hours 1 mg/ml OKT3 anti-CD3 (eBioscience) was added to the
cultures. After further 72 hours proliferation was measured by
flow cytometry as CFSE dilution in CD3+CD4+ (CD4 T cells) and
CD3+CD8+ (CD8 T cells) gated PBMC. Calculation of division
index (number of cell divisions/total cell number) and proliferation
index (number of cell divisions/number of divided cells) was
performed using FlowJo software (Treestar).
Preparation of the two-step experiment
PBMC were isolated from eight different donors. CD4+ and
CD8+ cells were separated from fresh PBMC using anti-CD4 and
anti-CD8 magnetic beads (Miltenyi Biotechs, Auburn, CA),
according to manufacturer instructions. The remaining PBMC were
cultured for 48 hours in presence of control microvesicles, AT-2
HIV or AT-2 HIV plus 1mT at the concentrations described above,
while the isolated CD4+ and CD8+ cells were maintained in RPMI
1640 (Invitrogen,) with 10% fetal bovine serum (Hyclone) and 1%
Pen-Strep-Glut (Invitrogen). After 48 hours, the non-adherent cells
from CD4+ and CD8+ cell cultures were collected and purity of CD4
and CD8 T cell population (.98% for both population) and
depletion of pDC (undetectable, see Supplemental Figure S1) were
determined by flow cytometry. Supernatants from the PBMC
cultures were collected and used as conditioned media (CM: control,
HIV, HIV+1mT). The autologous CD4 and CD8 T cells were
cultured in the three different CM in presence or absence of 1 mg/ml
OKT3 anti-CD3 (eBioscience) and 1 mg/ml anti-CD28
(eBioscience). Control experiments were performed by culturing
CD4 T or CD8 T cells in fresh media, in presence or absence of AT-
2 HIV or AT-2 HIV plus 1-mT, to discriminate between the effect of
tryptophan depletion and the cytopathic effect of AT-2 HIV which
may still be present in the CM.
Bioreduction cell proliferation assay
CD4 and CD8 T cells were cultured in the three different CM
in presence or absence of 1 mg/ml OKT3 anti-CD3 (eBioscience)
and 1 mg/ml anti-CD28 (eBioscience). After 72 hours prolifera-
tion was assessed as the increase in the number of viable cells,
using the CellTiter 96 AQueous One Solution Proliferation Assay
(Promega, Madison, WI), according to the manufacturer’s
instructions. Titration curves made with serial dilution of cells
were not modified by addition of 1-mT, demonstrating that the
compound does not influence the assay.
Annexin V staining
CD4 and CD8 T cells were cultured in the three different CM
in presence or absence of 1 mg/ml OKT3 anti-CD3 (eBioscience)
and 1 mg/ml anti-CD28 (eBioscience). After 72 hours cells were
washed in annexin buffer and incubated for 20 minutes with
medium only (negative control) or with fluorescein isothiocyanate
(FITC)–conjugated annexin V (Caltag, Burlingame, CA) at room
temperature. After 2 washes FACS analysis was performed on a
FACSCanto flow cytometer using FACSDiva software (BD
Biosciences). FlowJo software (Treestar, Ashland, OR) was used
to analyze flow cytometry data.
Flow cytometry cell cycle analysis
Cell cycle progress of CD4 and CD8 T cells was tested using the
FITC BrdU Flow Kit (BD Biosciences), according to the
manufacturer’s instructions. Briefly, CD4 and CD8 T cells were
pulsed for 2 hours with BrdU, then washed fixed and permeabi-
lized before treatment with DNase (1 hour at 37uC) to expose
BrdU epitopes. Cells were then washed and incubated with FITC-
conjugated anti-BrdU. After the final wash 7-AAD was added to
the cells for DNA content staining (all reagents were included in
the BD Biosciencesc FITC BrdU Flow Kit). FACS analysis was
performed on a FACSCanto flow cytometer using FACSDiva
software (BD Biosciences). FlowJo software (Treestar, Ashland,
OR) was used to analyze flow cytometry data.
Quantification of cyclins and CHOP mRNA
Total RNA was extracted from CD4 and CD8 T cells using the
guanidium thiocyanate-phenol-chloroform method, modified for
TRIzol (Invitrogen, Carlsbad, CA). RNA (1 mg) was reverse
transcribed into first strand cDNA by using random hexanucleo-
tide primers, oligo(dT), and Moloney murine leukemia virus
reverse transcriptase (Promega, Madison, WI). cDNA quantifica-
tion was performed by real-time PCR, conducted with an ABI
Prism 7900HT (Applied Biosystems, Foster City, CA). All
reactions were performed using a SYBR green PCR mix
(QIAGEN), according to the following thermal profile: denatur-
ation at 95uC for 15 sec, annealing at 60uC for 15 sec, and
extension at 72uC for 15 sec (data collection was performed during
the extension step). Primer sequences were designed using the
Primer3 software and are presented in Table 2. All results were
normalized on GAPDH mRNA expression. Cyclins mRNA results
Table 2. Primers used for real time PCR assays
Forward Reverse
GAPDH ccacccatggcaaattcc tgggatttccattgatgacaag
Cyclin D1 ccctcggtgtcctacttcaa aggaagcggtccaggtagtt
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are presented as ratio between anti-CD3/CD28-stimulated cells
and unstimulated cells.
Statistical analysis
All in vitro experiments were repeated on PBMC from at least
five different donors. Statistical analyses were performed using the
SPSS 13.0 software (SPSS Inc., Chicago, IL, USA). Differences
between treated and untreated cells were assessed using a two-
tailed paired Student’s t-test. Differences between HIV-1-infected
and uninfected donors were assessed using a non-parametric two-
tailed Mann-Whitney U test. In all cases P,0.05 was considered
statistically significant. Univariate distributions of flow cytometric
data were performed by probability binning, in 300 bins using
FlowJo software.
Supporting Information
Supplemental Figure S1 Depletion of pDC from CD4+ cells
over 48 hours culture. CD4+ cells were isolated from PBMC of
HIV-uninfected donors and maintained in culture media for
48 hours before being used in the two-step experiments, as
described in Material and Methods. The frequency of pDC
(CD123+BDCA2+) was monitored by flow cytometry in the non
adherent cells at the time of isolation (0h), after 24 hours of culture
(24h) and before use in the two-step experiment (48h). Flow
cytometry dot plots show the progressive loss of pDC from the non
adherent population over 48 hours.
Found at: doi:10.1371/journal.pone.0002961.s001 (2.30 MB TIF)
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